This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Thu May 23, 2013 6:22 am


All times are UTC - 8 hours [ DST ]




Post new topic Reply to topic  [ 2 posts ] 
Author Message
 Post subject: Glutamate
PostPosted: Sat Apr 15, 2006 8:38 am 
Offline
Family Elder
User avatar

Joined: Fri Sep 10, 2004 3:00 pm
Posts: 1889
Glutamate has often been cited as being involved in the cascade of events in MS. The following research suggests that there might be a drug to help (I must admit I found the article difficult to decipher).

Ian



http://www.msif.org/en/research/researc ... ptors.html


Top
 Profile  
 
 Post subject: Re: Glutamate
PostPosted: Sat Apr 15, 2006 10:20 pm 
Offline
Volunteer Moderator
User avatar

Joined: Sat Nov 20, 2004 4:00 pm
Posts: 2716
Bromley wrote:
I must admit I found the article difficult to decipher

I think I would file it under the "neuroprotection" category. They are using a drug to inhibit cell signaling cascades that are elicited by glutamate via the NMDA receptor. They're inhibitor acts via uncompetitive inhibition. While this might sound confusing at first, all it means that the drug binds to the NMDA receptor at a site other than the binding site for glutamate.

The term "uncompetitive inhibition" is carried over from enzyme kinetics since receptor binding kinetics is mathematically studied in the same way that enzyme kinetics are studied. For example, let's take the case of enzymes which have an active site where a substrate binds and undergoes chemical modification. If a drug binds to the active site and prevents the substrate from binding, then it's competitively inhibiting the enzyme. However, if a drug binds to some other site on the enzyme and causes some change in the enzyme, usually a change in the shape of the enzyme which perturbs the shape of the active site and prevents the chemical modification of the substrate, then the drug is said to act through uncompetitive inhibition. An uncompetitive inhibitor is distinguished by the fact that it only binds to the enzyme after the substrate has bound to the active site, i.e., it only binds to the enzyme substrate complex. This differs from a non-competitive inhibitor which acts in a similar fashion but can bind to either the enzyme alone or the enzyme substrate complex. So, with respect to the NMDA receptor antagonist used in the study it is binding to the receptor+glutamate complex and inhibiting the normal signaling cascades that usually occur as a result of glutamate thereby protecting the oligodendrocytes.

Anyways, it's been a while since I've had any biochemistry so I hope that the above explanation is clear enough.

NHE


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 2 posts ] 

All times are UTC - 8 hours [ DST ]


Related topics
 Topics   Author   Replies   Views   Last post 
There are no new unread posts for this topic. glutamate and progression

dignan

10

1460

Mon May 04, 2009 8:15 am

Mars View the latest post

There are no new unread posts for this topic. New research on glutamate receptor damage

[ Go to pageGo to page: 1, 2 ]

dignan

25

3998

Mon Jan 30, 2006 1:09 pm

mrhodes40 View the latest post

There are no new unread posts for this topic. HHV-6 induces dysregulation of glutamate uptake

Mars

1

806

Thu May 07, 2009 7:50 pm

marcstck View the latest post

 


Who is online

Users browsing this forum: CureOrBust


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: